Mustafa Husaini, MD
Cardiovascular Disease · Saint Louis, MONPI 1083032577
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $45,372 of the $71,304 with a category attached, or 63.6%. 18 manufacturers reported payments, led by E.r. Squibb & Sons, L.L.C. at 57.1% of the total. 2025 is the largest year on record at $29,367, more than ten times the $276 reported in 2019. Among cardiovascular disease clinicians in MO with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 129 payments — averaging $552.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- E.r. Squibb & Sons, L.L.C.$41K
- Amgen$15K
- United Imaging Healthcare North America, Inc.$13K
- Novo Nordisk$674
- Novartis$498
- Abbott$319
- plus $1K from 12 others
Across 10 payments — averaging $39,368 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Amgen$233K
- Novartis$161K
What the payments were for
- Consulting fees$13,00018%
- Speaking & faculty fees$45,37264%
- Travel & lodging$6,2599%
- Food & beverage$6,6739%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| E.r. Squibb & Sons, L.L.C. | 57 | $40,691 |
| Amgen | 33 | $14,969 |
| United Imaging Healthcare North America, Inc. | 1 | $13,000 |
| Novo Nordisk | 10 | $674 |
| Novartis | 8 | $498 |
| Abbott | 6 | $319 |
| Medtronic | 1 | $156 |
| Heartflow, Inc. | 1 | $147 |
| Abiomed | 2 | $135 |
| AstraZeneca | 1 | $130 |
| United Therapeutics Corporation | 1 | $125 |
| Boston Scientific | 2 | $120 |
| Philips North America LLC | 1 | $88 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $87 |
| Agepha Pharma FZ LLC | 1 | $82 |
| Bracco Diagnostics Inc. | 1 | $37 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $33 |
| Pfizer | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CAMZYOS$39,616
- Repatha$13,904
- ULTRASOUND$13,000
- LEQVIO$354
- ENDURANT IIS$156
- FFRct$147
- Xience Sierra Coronary Stent System$147
- BRILINTA$130
- ENTRESTO$126
- ORENITRAM$125
- Impella$118
- SYNERGY$109
How this compares
$71,304 in reported general payments places this provider in the 90th percentile of 391 cardiovascular disease providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 322 | $371,302 |
| Repatha SureclickEvolocumab | 174 | $119,886 |
| FarxigaDapagliflozin Propanediol | 82 | $96,956 |
| OzempicSemaglutide | 82 | $89,252 |
| XareltoRivaroxaban | 72 | $76,690 |
| EntrestoSacubitril/Valsartan | 59 | $69,591 |
| JardianceEmpagliflozin | 85 | $69,400 |
| Repatha SyringeEvolocumab | 42 | $41,072 |
| Praluent PenAlirocumab | 51 | $35,511 |
| Metoprolol Succinate | 438 | $4,843 |
| Ezetimibe | 225 | $3,813 |
| Atorvastatin Calcium | 378 | $3,046 |
| Losartan Potassium | 347 | $2,966 |
| Spironolactone | 323 | $2,502 |
| Torsemide | 136 | $2,319 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $13 | $371,302322 claims |
| AstraZenecaFarxiga | $130 | $96,95682 claims |
| Novo NordiskOzempic | $674 | $89,25282 claims |
| NovartisEntresto | $498 | $69,59159 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 391 cardiovascular disease providers in Missouri.
Other cardiovascular disease in Saint Louis
- Georges ChahoudSaint Louis$937K
- William BowenSaint Louis$726K
- Daniel KellySaint Louis$582K
- Osler Jay GuzonSaint Louis$211K
- Mohammad TahirSaint Louis$173K
- Robert RifkinSaint Louis$145K
- Martin SchwarzeSaint Louis$113K
- Joshua MitchellSaint Louis$103K
- Zainab MahmoudSaint Louis$100K
- Nizar AssiSaint Louis$81K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.